After years of fighting over compounded weight loss drugs, Hims & Hers and Novo Nordisk are teaming up to sell Ozempic and Wegovy — a shift that could raise costs for patients.

Hers is currently offering 20% off GLP-1 medication for eligible subscribers who pay over $500 for weight-loss services.

Shares of telehealth company Hims & Hers skyrocketed Monday after the company struck a deal with Danish drugmaker Novo Nordisk to sell its GLP-1 weight-loss medications, ending the feud between the ...

Novo dropped its patent-infringement case against telehealth provider Hims & Hers after the companies agreed that Hims would sell Novo's branded medicines.

The companies have been embroiled in a row about compounded GLP-1 drugs that escalated to a lawsuit last month. The legal action has now been dropped and the former adversaries have struck a deal that ...

The FDA is taking no prisoners as it continues its efforts to combat widespread GLP-1 drug compounding. | In the letters sent ...

Telehealth company Hims & Hers on Monday announced a “strategic shift” in its business model, partnering with pharmaceutical company Novo Nordisk to sell its blockbuster GLP-1 medication and stop ...

Add Yahoo as a preferred source to see more of our stories on Google. A vial with injectable compound and a syringe. - Anna Hoychuk // Shutterstock Compounded semaglutide is a medication that’s custom ...

Drug executives say only their GLP-1 drugs are safe for treating obesity and diabetes as they wage a year-long campaign to ...

The Food and Drug Administration’s crackdown on cheaper, independently produced versions of popular weight-loss and diabetes medications stoked anger and pushback from users, sellers and the Alliance ...

The agreement brings an end to the legal dispute between the two companies. Hims & Hers shares jumped.

The FDA issued warning letters to 30 telehealth companies over misleading claims about compounded versions of popular weight-loss drugs like Ozempic and Zepbound.